Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations - Wikidata - wikimedia - TriplyDB

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

http://www.wikidata.org/entity/Q35100315

about

Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.Rates of BRCA1/2 mutation testing among young survivors of breast cancer Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients.Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.Online tool to guide decisions for BRCA1/2 mutation carriers.Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.Locoregional treatments for triple-negative breast cancer.Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer.Long-term treatment after preoperative high-dose chemotherapy in a lactating breast cancer patient.The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis.Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?The prognostic impact of age in patients with triple-negative breast cancer.The role of BRCA status on prognosis in patients with triple-negative breast cancer.Roles and expression profiles of long non-coding RNAs in triple-negative breast cancers.Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.BRCA mutations in women with inflammatory breast cancer.BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients.Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.

P2860

Q21999477-1C34CEC1-02E0-42C8-B96F-761C9479DA05 Q33739351-3AEB7125-97A5-4E2D-89CE-0DC47CF9E2AC Q33923031-1BEAE446-8832-424C-AA39-3D73A3AF9970 Q34038170-5B8D24C2-353A-4C30-8E5A-719380582471 Q34460831-49A9F81D-C78C-4E6E-825D-2540DA42B970 Q34613122-941F7363-BC89-4F83-9F3C-623FF888632F Q35105646-CF442DBE-7244-4AA4-B32B-CA818CA418C3 Q35224593-DAB50AB8-B468-4408-A1EE-4E57BEBA01B6 Q35695425-FF9596B1-835C-479A-8323-4E9507CCCF46 Q35722508-6BFB51C5-E5AB-4D42-BA5A-63D5FE5E9C64 Q35808372-F3D6C19A-481E-4DA9-BC21-2BA42E9BD868 Q36003635-46929AC2-2975-4A97-ABEE-CAF1CBE10574 Q36009795-86B6CC04-B0F1-4C4E-B23F-79D9A3E56CDD Q36110709-90BE64FB-72D3-4FB9-B276-B2749D5A0A1B Q36160180-988F2413-BBA7-47E8-A08B-61A1A011E6D0 Q37317308-62F95BB9-503F-4BB5-B11C-29CDF222C4D2 Q37379689-E2DB7E1F-CE25-40C7-A1D2-860527009337 Q37388751-CD3A46D8-A37B-4C87-9DB5-703A127034B8 Q38046579-706A2F47-7152-46E6-AC02-A04B37197016 Q38047337-40380D89-11C7-48AE-AA20-5749E6C4A73D Q38087850-10E80213-FEA3-415F-A743-9DC558D2D72C Q38107807-500F89EF-E00C-4558-BB23-98CC2220AAF1 Q38148063-A27C3D7E-A4E5-4538-A0F2-52BA2060B2C4 Q38190005-F3B28D09-0ED6-4B6C-A649-7442379E1AA3 Q38806371-50AD67D8-4C9E-4FFA-B449-7DD772ED3B58 Q38876050-8CA3B92C-02E7-4F39-BA12-A304E0D5E66A Q44429695-F94433D2-1FE6-4971-B012-15767478578D Q44462595-88CA7814-710E-47F2-B994-1DE48E8E42B8 Q44535570-2CE970AF-808D-4705-88E7-6F98FCF5CCF1 Q44732177-1CCA0E85-6C7E-48BC-B045-67A484C85E4B Q45719058-CA0A36FB-656F-4AD9-82AD-C95558E438BF Q47097677-C433FDFE-0C70-4974-8105-F459B0F805B2 Q47125532-499BF4B5-1A49-442C-A3B3-DC030B18B281 Q47246829-CD01AE41-F136-439C-AE34-57A7D4D51DF8 Q47769924-DEBA5950-A97E-47B7-9372-CBDC8CD6824F Q50108671-7B84DE9D-166A-42B3-812C-0ADFCA033083 Q50604147-BDBB9B16-E728-450A-A33D-E7748028C80E Q51293206-34EA4AA4-0FFE-45C0-9EA7-9DE5E8CA6F32 Q51684386-6B023F33-A717-4839-B2F1-7EC0787CC3B4 Q54336161-82010CC4-ED11-4D18-8C0B-5B38C20C7464

P2860

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

http://www.wikidata.org/entity/Q35100315

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Outcome of triple-negative bre ...... out deleterious BRCA mutations

@ast

Outcome of triple-negative bre ...... out deleterious BRCA mutations

@en

type

label

Outcome of triple-negative bre ...... out deleterious BRCA mutations

@ast

Outcome of triple-negative bre ...... out deleterious BRCA mutations

@en

prefLabel

Outcome of triple-negative bre ...... out deleterious BRCA mutations

@ast

Outcome of triple-negative bre ...... out deleterious BRCA mutations

@en

P1433

Q35100315-F5B667CF-DF7E-466B-BD23-FF82C33A8679

P1476

Q35100315-F153B42C-D808-46DF-90D4-906F88CF2D31

P2093

Q35100315-07EC3AA4-FEB2-4BCE-B73B-BE8641CC4B9C

Q35100315-14010546-E18C-4F32-8243-5A33B3AE453F

Q35100315-1F02F34C-E029-4BA7-BDDE-5C997A6AD081

Q35100315-6F2DD0ED-FDCB-4177-9CE5-47ACE1E5E9E5

Q35100315-7F8A9CFD-D5F2-443C-9F56-CD3A24FF5E79

Q35100315-A8DC3E07-216D-42C2-9ECE-6975B2AF0CC4

Q35100315-AD5C06C4-56BD-4960-A689-544DB3FAF45B

Q35100315-BA0EB39A-2850-4DCA-BCBC-812396786E7E

Q35100315-BAA88951-BBC6-4A6B-AC2B-B9EA8D8EAC17

Q35100315-DA2F904C-108E-4B7A-9D1D-06ED61EA728B

P2860

Q35100315-04590317-EA7B-4187-8B74-2C0094EAB776

Q35100315-09F2EC0D-B6EB-428F-A960-22CA61A66CEA

Q35100315-0B4F06DA-9E49-4718-87C3-CA622386A909

Q35100315-1746CCE5-0199-43AC-9DB4-2D55235D8652

Q35100315-223A0E6A-C3C5-439C-BBF0-68EB61D166D6

Q35100315-2AF66D9C-7155-4C52-AEB4-BE58CDFADE12

Q35100315-3150517C-28D4-43FF-90F4-8D013F31D1FF

Q35100315-38987BED-24AA-42B1-B390-109C1E4C7817

Q35100315-3A76AB61-EEF5-4426-99AF-247060037CEC

Q35100315-47BC2351-50E8-40CC-ABF1-5FB2A8D9D931

P2888

Q35100315-7F12A391-E04A-4001-8F5E-499F373B40D8

P304

Q35100315-015CE34D-42BD-4CF4-9D40-EA1181D23889

P31

Q35100315-9348C596-F882-4511-8BCF-073A26091501

P356

Q35100315-35073566-B89B-4A47-8F3A-897A183455E3

P407

Q35100315-69D5E6E7-BE43-4CD5-98B3-CEE26C021E37

P433

Q35100315-7F473C72-CB49-46BC-BD0B-94F4A6B7E897

P478

Q35100315-77EA7B75-F513-448A-8900-402C134C3278

P50

Q35100315-3BCC9BA8-F901-49D5-8D2C-FADC1ABBB650

P577

Q35100315-465E719F-E1ED-4676-96B8-8F4FF946B23F

P698

Q35100315-44AFBC46-49E4-44FB-8449-BADFA900FA27

P932

Q35100315-99EEBA1E-4FC0-44DB-A51B-3CEFF009F9B5

P356

S10549-011-1711-Z

P1433

Breast Cancer Research and Treatment

P1476

Outcome of triple-negative bre ...... out deleterious BRCA mutations

@en

P2093

Ana M Gonzalez-Angulo

http://www.w3.org/2001/XMLSchema#string

Angelica M Gutierrez-Barrera

http://www.w3.org/2001/XMLSchema#string

Banu K Arun

http://www.w3.org/2001/XMLSchema#string

Constance T Albarracin

http://www.w3.org/2001/XMLSchema#string

Diane Liu

http://www.w3.org/2001/XMLSchema#string

E Lin

http://www.w3.org/2001/XMLSchema#string

Gabriel N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

Jennifer K Litton

http://www.w3.org/2001/XMLSchema#string

Soley Bayraktar

http://www.w3.org/2001/XMLSchema#string

Tunc Tasbas

http://www.w3.org/2001/XMLSchema#string

P2860

A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Molecular portraits of human breast tumours

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Repeated observation of breast tumor subtypes in independent gene expression data sets

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

Hallmarks of 'BRCAness' in sporadic cancers

Survival in hereditary breast cancer associated with germline mutations of BRCA2.

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.

P2888

s10549-011-1711-z

P304

145-153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-011-1711-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

Funda Meric-Bernstam

P577

2011-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21830012

http://www.w3.org/2001/XMLSchema#string

P932

4334122

http://www.w3.org/2001/XMLSchema#string